(1R,8R,9R)-5-methyl-16-azatetracyclo[6.5.3.01,9.02,6]hexadeca-2(6),3-diene

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚和异茚
• 英文名称: (1R,8R,9R)-5-methyl-16-azatetracyclo[6.5.3.01,9.02,6]hexadeca-2(6),3-diene
• 化学式: C₁₆H₂₃N
• 分子量: 229.36
• InChiKey: XBKSVCGHJYIJLI-LVMUYBQDSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• BIOAVAILABILITY OF ORAL METHYLNALTREXONE INCREASES WITH A PHOSPHATIDYLCHOLINE-BASED FORMULATION
  申请人：The University of Chicago

  公开号：EP2854537A1

  公开（公告）日：2015-04-08
• [EN] BIOAVAILABILITY OF ORAL METHYLNALTREXONE INCREASES WITH A PHOSPHATIDYLCHOLINE-BASED FORMULATION<br/>[FR] AUGMENTATIONS DE LA BIODISPONIBILITÉ DE MÉTHYLNALTREXONE ORALE PAR UNE FORMULATION À BASE DE PHOSPHATIDYLCHOLINE
  申请人：UNIVERISTY OF CHICAGO

  公开号：WO2013165577A1

  公开（公告）日：2013-11-07

  A pharmaceutical composition comprising a phosphatidylcholine-based opioid receptor antagonist formulation, as well as methods of their use and methods of their preparation are provided herein. Such pharmaceutical composition may be used for treating and preventing opioid-induced side effects in patients, and may be provided to chronic opioid users as well.